Immune evasion by neocartilage-derived chondrocytes: Implications for biologic repair of joint articular cartilage  by Adkisson, H.D. et al.
ava i l ab l e a t www.sc i enced i r ec t . com
www.e l sev i e r . com/ loca te / sc r
Stem Cell Research (2010) 4, 57–68REGULAR ARTICLE
Immune evasion by neocartilage-derived
chondrocytes: Implications for biologic repair of
joint articular cartilage
H.D. Adkisson a,⁎, C. Milliman a, X. Zhang b, K. Mauch b,
R.T. Maziarz b, P.R. Streeter ba ISTO Technologies, Inc., 1155 Olivette Executive Parkway, St. Louis, MO 63132, USA
b Oregon Stem Cell Center, OHSU Knight Cancer Institute, Division of Hematology & Medical Oncology,
3181 SW Sam Jackson Park Road, Oregon Health & Science University, Portland, OR 97239, USAReceived 8 April 2009; received in revised form 28 August 2009; accepted 18 September 2009Abstract Degenerationof joint articular cartilage is a leading cause of disabilityworldwide, and is due in largepart to the fact that
adult articular cartilage is unable to undergo effective intrinsic repair. To overcome this barrier, we have developed a tissue
engineering strategy which harnesses the superior anabolic activity of juvenile chondrocytes to produce a scaffold-independent,
living neocartilage graft. Preclinical studies demonstrate that bioengineered neocartilage survives allogeneic and xenogeneic
transplantation, suggesting the utility of universal donor-derived neocartilage for joint repair. However, themechanism underlying
neocartilage transplant tolerance remains poorly understood. We show here that neocartilage-derived chondrocytes are unable to
stimulate allogeneic T cells in vitro, and they do not constitutively express cell surface molecules required for induction of T cell
immune responses, including major histocompatibility complex (MHC) Class II antigens and costimulatory molecules B7-1 and B7-2.
Additionally, chondrocytes suppress, in a contact-dependent manner, the proliferation of activated T cells, with suppression
associated with chondrocyte expression of multiple negative regulators of immune responses, including B7 family members (B7-H1,
B7-DC, B7-H2, B7-H3, and B7-H4), chondromodulin-I and indoleamine 2,3-dioxygenase. Thus, the survival of transplanted
bioengineered neocartilage may depend on both passive and active mechanisms of immune evasion.
© 2009 Elsevier B.V. All rights reserved.Introduction
Adult articular cartilage has a limited regenerative capacity.
As a consequence, adults whose cartilage has been damaged
by arthritis, trauma, or other insult often suffer from chronic
pain and disability. Transplantation of laboratory-engi-
neered cartilage, known as neocartilage, may be a thera-
peutic option for these individuals (Feder et al., 2004;
Hunziker, 2002). Neocartilage is generated in vitro using⁎ Corresponding author. Fax: +1 314 995 6025.
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doi:10.1016/j.scr.2009.09.004chondrocytes, the cellular components of articular cartilage,
obtained from juvenile cadaveric donors (Adkisson et al.,
2001). Cells from a single donor can be scaled in vitro to
meet the transplant needs of multiple recipients. Previous
studies have demonstrated that juvenile human chondro-
cytes are up to 100-fold more efficient than adult chon-
drocytes in producing bioengineered cartilage (Feder et al.,
2004; Adkisson et al., 2001).
With most tissues, transplantation across allogeneic
barriers carries a significant risk of immune rejection,
necessitating tissue matching and/or the use of immunosup-
pressive agents. Immune rejection of transplanted tissue.
Figure 1 Gross macroscopic and histological appearance of
cartilage repair in the sheep knee following allogeneic neocarti-
lage implantation. (a) A 6 mm circular defect created in the
central aspect of the medial femoral condyle showing removal of
native articular cartilage to the subchondral bone surface without
bleeding (0.75 mm). (b) At 8 weeks after implantation, the defect
was filled with repair tissue and the interface between repaired
tissue and surrounding host articular cartilage was unremarkable
(white dashed circle). (c) Safranin-O/fast green stained midsag-
ittal section from an ovine allograft showing integrative repair at
both the lateral and the subchondral interface. The cell density of
implanted neocartilage (NC) is greater than that of adjacent host
cartilage (HC), illustrating intense metachromatic staining for
sulfated glycosaminoglycans. Arrow designates the graft/host
junction. Original magnification×100.
58 H.D. Adkisson et al.occurs when the recipient's T lymphocytes recognize grafted
tissue as “nonself” (Bretscher and Cohn, 1970). T lymphocyte
priming, a requisite step in the rejection process, requires T
cell receptor (TCR) ligation and engagement of CD28, the
receptor for the costimulatory molecules B7-1 (CD80) and B7-
2 (CD86) (Bretscher , 1999). These stimulatory signals can be
delivered to the graft recipient's T lymphocytes by direct
contact with cell surface molecules on transplanted alloge-
neic cells or by presentation of allogeneic antigens by the
recipient's antigen presenting cells (APC).
Articular cartilage is viewed as an immune privileged
tissue. Cartilage is rarely a target of autoimmune disease
(Balanescu et al., 2002; Fox, 1997), and transplanted
cartilage from unrelated donors does not elicit immune
rejection responses (Chesterman and Smith, 1968; Elves and
Zervas, 1974; Lance and Fisher, 1970). Further, fresh shell
osteochondral allografts have been used successfully in the
clinic for more than three decades without immunosuppres-
sive agents to repair large osteochondral defects in young
active patients (Maury et al., 2007; Williams et al., 2007).
Cartilage structure and cellular composition may contribute
to the absence of immune rejection responses and subse-
quent allograft survival. Structural features of cartilage,
including its avascular nature and the extensive extracellular
matrix that surrounds chondrocytes, may limit leukocyte
access into this tissue (Elves and Zervas, 1974; Bacsich and
Wyburn, 1947; Heyner, 1969). At the cellular level, cartilage
is devoid of APC such as histiocytes, and chondrocytes may
not effectively stimulate antigraft immune responses.
Chondrocyte immune privilege is further supported by the
survival and subsequent formation of repair cartilage
following implantation of allogeneic chondrocytes delivered
in the presence or absence of a carrier matrix in higher order
animals, including chickens, rabbits, sheep, and horses
(Chesterman and Smith, 1968, Hendrickson et al., 1994; Lu
et al., 2005; Rahfoth et al., 1998; Robinson et al., 1990).
Preclinical evaluations of bioengineered neocartilage
transplanted into surgical defects created in the knee joint
have demonstrated that this tissue, like joint-derived articular
cartilage, is not rejected when transplanted into genetically
unrelated recipients (Feder et al., 2004; Lu et al., 2005). This
report elucidates the immunobiological properties of chon-
drocytes recovered from neocartilage. We demonstrate that
human juvenile chondrocytes derived from bioengineered
neocartilage lack cell surface markers required for induction
of immune responses; that they do not induce alloantigen-
specific proliferative immune responses in vitro; and that they
actively suppress, in a contact-dependent manner, the
proliferation of activated T cells. These findings support the
concept that both passive and active mechanisms of immune
evasion facilitate neocartilage allograft survival.Figure 2 Neocartilage-derived juvenile chondrocytes do not stimula
marrow-derived dendritic cells (BMDC) generated in vitro from the sam
dependent proliferation of allogeneic responder PBL (thymidine inco
juvenile chondrocytes did not promote PBL proliferation at any cell con
proliferation. (b) FACS analysis comparing expression of cell surface
neocartilage-derived chondrocytes obtained from 6-week-old male and
Class II (HLA-DR), CD123, CD40, B7-1(CD80), B7-2(CD86), and the adhe
for thesemarkers. Specific staining illustrated by filled histogram; isoty
juvenile chondrocytes stimulatedwith 200 Units/mL of recombinant hu
and II (HLA-DR). Specific staining is shown with black histogram; isotyResults
Chondrocyte immunogenicity
Preclinical studies have demonstrated the survival and
integration of bioengineered neocartilage into experimentalte allogeneic T cell proliferation. (a) After 7 days of culture, bone
e donor tissue used to produce neocartilage promotedpotent dose-
rporation; counts per minute). In contrast, neocartilage-derived
centration evaluated. Responder PBL alone also exhibited baseline
markers characteristic of antigen presenting cells on BMDC and
8-year-old female donors. BMDC showed positive staining for MHC
sion molecule CD11c. Resting juvenile chondrocytes were negative
pe control is shownwith open histogram. (c) Neocartilage-derived
man IFN-gamma show increased staining for MHC Class I (HLA-ABC)
pe control is illustrated with gray histogram.
59Immune evasion by neocartilage chondroctyesdefects created in healthy joint surfaces (Feder et al., 2004;
Lu et al., 2005). These studies, conducted in xenogeneic and
allogeneic transplant models, have revealed no gross
macroscopic or histological evidence of immune rejection.
Ovine neocartilage has been transplanted into ovine reci-pients, and human neocartilage has been transplanted into
leporine, ovine, and caprine recipients. A representative
outcome following allogeneic transplantation of neocarti-
lage into a young-adult sheep is presented in Fig. 1. A full
thickness defect in the most weight bearing region of the
Figure 3 Analyses of major histocompatibility complex and
costimulatory molecule expression in neocartilage-derived ju-
venile chondrocytes and adult articular chondrocytes. (a) RT-PCR
analyses demonstrating that B7-1 (CD80) and B7-2 (CD86) mRNA
were undetectable in juvenile chondrocytes. By contrast, B7-1
(CD80) and B7-2 (CD86) mRNA was detected in adult articular
chondrocytes. Glyceraldehyde-3-phosphate dehydrogenase
60 H.D. Adkisson et al.knee is shown prior to transplantation (Fig. 1a) and at
8 weeks following transplantation (Figs. 1b and c). Gross
macroscopic and histological examination revealed repair of
the defect, with integration of donor neocartilage and no
observable damage to the opposing joint surface.
In light of these findings, the immunogenicity of human
neocartilage-derived juvenile chondrocytes was investi-
gated using nondividing chondrocytes as stimulator cells
and human peripheral blood leukocytes (PBL) as responder
cells in mixed lymphocyte–chondrocyte reaction assays
(MLCR). For this series of assays, varying numbers of irra-
diated (3000 rad) chondrocytes (102–104) were mixed with
2×105 allogeneic PBL. Chondrocytes used for this aspect of
the study were derived from enzyme-dissociated neocar-
tilage (Adkisson et al., 2001). Lymphocyte proliferation
was quantitated by [3H]thymidine incorporation after 5–6
days of coculture. Neocartilage-derived chondrocytes from
13 of 14 juvenile donors did not stimulate allogeneic PBL
proliferation (Fig. 2a and Table 1). By contrast, one chon-
drocyte preparation elicited a weak response above base-
line (Table 1; chondrocytes from a 1.2 year old female
donor yielded a response from one of two donor PBL spe-
cimens that was 1.9 times higher than the negative con-
trol). As a positive control, the stimulatory potential of
irradiated (3000 rad) bone marrow dendritic cells (BMDC)
generated in vitro from each of the chondrocyte donors
was evaluated. These potent APC readily stimulated the
proliferation of allogeneic PBL (Fig. 2a and Table 1). Thus,
in contrast to the potent stimulatory capacity of BMDC,
allogeneic juvenile chondrocytes derived from the same
donor tissues did not stimulate T lymphocyte proliferation
in vitro.
The inability of neocartilage-derived juvenile chondro-
cytes to stimulate T cell proliferation in vitro may relate to(GAP) was included to demonstrate equal loading of RNA. Note
that the 44-year-old adult sample was underloaded (40%) due to
limited sample availability. (b) FACS analysis comparing expres-
sion of MHC Class I and Class II molecules on adult resting and
recombinant human IFN-gamma-activated chondrocytes. Chon-
drocyte stimulated with 200 Units/mL of recombinant human
IFN-gamma show increased staining for MHC Class I (HLA-ABC)
and II (HLA-DR). Specific staining is shown with black histogram;
isotype control is illustrated with gray histogram.
Table 1 Comparison of chondrocyte and bone marrow
dendritic cell allostimulatory activity in the mixed
lymphocyte chondrocyte reaction
Donor age Donor sex Chondrocyte MLCR a BMDC MLCR a
5 weeks Female – ++
6 weeks Male – NA
2 months Male – ++
3 months Male – ++
3 months Female – ++
3 months Male – +
3 months Male – +++
4 months Female – +++
1.2 years Female +/– b ++
2.6 years Male – +++
2.75 years Male – +++
5 years Female – ++
6 years Male – NA
8 years Male – NA
a –=b1.5-fold above background; +=1.5-fold to b10-fold
stimulation at 104 cells; ++=10-fold to b40-fold stimulation at
104 cells; +++=N40-fold stimulation at 104 cells.
b Chondrocytes from this donor elicited a weak proliferative
response from one of two PBL donors (1.9 fold above
background). The response of PBL from the second PBL donor
was b1.5-fold above background.the absence of molecules required for immune response
induction (Bretscher and Cohn, 1970; Bretscher, 1999). To
test this concept, we evaluated cell surface marker expres-
sion on neocartilage-derived juvenile chondrocytes. Flow
cytometric analysis revealed that resting juvenile chondro-
cytes express neither MHC Class II (HLA-DR), which presents
peptide epitopes to CD4+ T cells via the TCR, nor the cos-
timulatory molecules B7-1 (CD80) and B7-2 (CD86) (Fig. 2b)
which serve as ligands for CD28 binding. Further, serial
passage of these cells (from P0 to P2, approx 6-8 population
doublings) did not alter this expression profile (not shown). In
contrast, immune stimulatory BMDC were shown by flow
cytometric analysis to express MHC Class II, B7-1 (CD80), and
B7-2 (CD86), CD11c, CD40, CD123 and the leukocyte lineage
(LIN) markers CD3, CD14, CD16, CD19, CD20, or CD56 (Fig.
2b). Thus, neocartilage-derived juvenile chondrocytes
61Immune evasion by neocartilage chondroctyesappear to lack cell surface expression of molecules required
for T cell activation.
Recent studies of the mechanisms associated with
allograft rejection suggest that rejection may occur as a
consequence of trauma associated with the transplant
procedure. Those studies implicate inflammatory cytokines,
such as IFN-gamma, in the activation of APC and subsequent
immune rejection (Mellor and Munn, 2004). To model this
process in vitro, neocartilage-derived juvenile chondrocytes
were treated with IFN-gamma, which resulted in the
upregulated cell surface expression of MHC Class I (HLA-
ABC)molecules, and a small increase inMHCClass II (HLA-DR).Figure 4 Articular chondrocytes are immunosuppressive and disp
Neocartilage-derived juvenile chondrocytes inhibited the prolifera
allogeneic PBL or irradiated (3000 rad) allogeneic BMDC were used a
articular cartilage actively inhibited in a dose-dependent manner t
Polyclonal activation was achieved by exposure of CD4+ T cells to ant
of chondrocytes and polyclonally activated PBL demonstrated that c
cell contact with T lymphocytes. Data are representative of three sHowever, no increase in expression of the costimulatory
molecules B7-1 (CD80) and B7-2 (CD86) was observed by flow
cytometry (Fig. 2c). Further, IFN-gamma-activated chondro-
cytes, like their unstimulated counterparts, failed to elicit
proliferation of allogeneic PBL in vitro (not shown). In
summary, exposure of neocartilage-derived juvenile chon-
drocytes to IFN-gamma promoted expression of MHC Class I
and II molecules, but this change in surface antigen
expression did not yield chondrocytes with the ability to
simulate alloantigen-specific T cell proliferation in the MLCR.
To further address the question of chondrocyte immuno-
genicity, we evaluated the phenotype and function of adultlay contact-dependent immunosuppressive activity in vitro. (a)
tion of alloantigen-activated PBL, when irradiated (1000 rad)
s stimulator cells. (b) Juvenile (neocartilage-derived) and adult
he proliferation of polyclonally activated CD4+ T lymphocytes.
ibodies directed against CD3 and CD28. (c) Transwell separation
hondrocyte-mediated immunosuppressive activity requires cell–
eparate experiments using neocartilage-derived chondrocytes.
62 H.D. Adkisson et al.chondrocytes. In contrast to juvenile neocartilage-derived
chondrocytes, adult chondrocytes were found by RT-PCR to
express B7-2 and to a lesser extent B7-1 mRNA (Fig. 3a).
Adult chondrocytes also express MHC Class I and low levels of
MHC Class II; and when exposed to IFN-gamma these cells
were found to up-regulate cell surface expression of MHC
Class I (HLA-ABC) and MHC Class II (HLA-DR; Fig. 3b). Further,
cytokine-activated adult chondrocytes, like their juvenile
counterparts, did not induce allogeneic T cell proliferation
in vitro (not shown). Thus, despite expression of cell surface
molecules involved in T cell activation, adult chondrocytes
failed to stimulate T cell proliferation in the MLCR. These
findings suggested that chondrocytes actively inhibit or
suppress lymphocyte proliferation in vitro.
Chondrocyte-mediated immune suppression
The immune suppressive potential of chondrocytes was
evaluated using multiple strategies. Initial studies assessed
suppression of proliferative responses to alloantigen. For
these experiments, responder PBL were stimulated using
either irradiated (1000 rad) allogeneic PBL or irradiated
(3000 rad) allogeneic BMDC (Fig. 4a). Stimulation with either
of these sources of alloantigen resulted in proliferation of
responder PBL. The addition of irradiated (3000 rad)
neocartilage-derived juvenile chondrocytes to these culturesFigure 5 RT-PCR analysis of gene expression for immune inhibi
chondrocytes from neocartilage-derived juvenile and adult articular
B7-H4 mRNA, reported negative regulators of T cell function, was de
mRNA, a negative costimulatory molecule with inducible kinetics (
adult chondrocytes. Chondromodulin-I mRNA encoding the cartilag
pressive activity to polyclonally activated T cells in vitro (Setogu
chondrocytes. Note, however, that ChM-I gene expression was undet
for detection of each of the B7 costimulatory family members.resulted in the inhibition of T cell proliferation induced by
either source of alloantigen (Fig. 4a).
The studies described above revealed that the addition of
chondrocytes to mixed lymphocyte cultures inhibited T cell
proliferation. To determine if chondrocytes acted directly on
responding T cells or indirectly via accessory cells such as B
cells or monocytes, neocartilage-derived juvenile chondro-
cytes were coincubated with purified CD4+ T cells that were
activated by cross-linking both the TCR/CD3 complex with an
anti-CD3 specific antibody and the B7-1/B7-2 receptor (CD28)
with an antibody directed against CD28. This combination of
antibodies delivers a strong activation signal to CD4+ T cells, as
is evidenced by robust T cell proliferation (Fig. 4b). Addition of
irradiated neocartilage-derived juvenile chondrocytes to
these cultures resulted in a dose-dependent decrease in T
cell proliferation (Fig. 4b). Similarly, adult chondrocytes
potently inhibited proliferation of activated T cells (Fig. 4b).
Thus, chondrocytes suppress CD4+ T cell proliferative
responses by direct action on the responding T cells.
The immune suppressive property of neocartilage-derived
juvenile chondrocytes was further assessed by physically
separating these cells from activated CD4+ T cells using 0.2-
μm pore size transwell inserts. These inserts allow passage of
soluble mediators between cells in the two chambers, but
prevent direct cell–cell contact. Under these conditions,
neocartilage-derived juvenile chondrocytes failed totory members of the B7 family of costimulatory molecules in
cartilage. Constitutive expression of B7-DC, B7-H2, B7-H3, and
tected in all chondrocyte populations surveyed, whereas B7-H1
below) showed variable constitutive expression in juvenile and
e-specific cell surface protein reported to display immunosup-
chi et al., 2004) was readily identified in juvenile and adult
ectable in the chondrosarcoma cell line used as a positive control
Figure 6 Articular chondrocytes express indoleamine 2,3-
dioxygenase (IDO) mRNA and protein on cytokine activation. (a)
RT-PCR analysis showing inducible expression of IDO mRNA after
a 72 h treatment of neocartilage-derived juvenile chondrocytes
with 200 Units/mL IFN-gamma. GAP mRNA served as a loading
control. (b) Protein expression was demonstrated by Western
blotting of lysates prepared 72 h after activation with the
indicated proinflammatory cytokines. The PVDF membrane was
probed for IDO protein using a monoclonal antibody (clone 10.1)
purchased from Upstate (Lake Placid, NY), according to
manufacturer's instructions. (c) Pharmacologic inhibition of
IDO activity using 1-methyl tryptophan (Sigma-Aldrich) partially
inhibited the immunosuppressive activity of chondrocytes that
were added to polyclonally activated T lymphocytes at the
intermediate concentration (3×104) but not at the highest
concentration of chondrocytes analyzed.
63Immune evasion by neocartilage chondroctyessuppress the proliferation of CD4+ T cells activated with
antibodies directed against CD3 and CD28, suggesting that
chondrocyte-to-T cell contact is required for inhibition of
CD4+ T cell proliferation (Fig. 4c).
Candidate mechanisms of chondrocyte-mediated
immune suppression
Expression of immune inhibitory B7 family members
In addition to providing positive stimulatory signals, the B7
family of cell surface molecules contains several members
that transmit inhibitory signals to T cells (Greenwald et al.,
2005). B7-H1 and B7-DC block the early stages of T cell
activation via the PD-1/PD-2 receptor (Freeman et al., 2000;
Latchman et al., 2004); B7-H4 inhibits activated T cells
through an unknown receptor (Sica et al., 2003); and B7-H3
also negatively modulates T cell responses (Suh et al., 2003).
We analyzed by RT-PCR neocartilage-derived juvenile chon-
drocytes and native adult articular cartilage chondrocytes for
expression of B7 family members that have been implicated as
negative regulators of T cell function. B7-DC, B7-H2, B7-H3,
and B7-H4 mRNA were constitutively expressed at high levels
in most specimens (Fig. 5). By contrast, constitutive expres-
sion of B7-H1 mRNA was low in both juvenile (neocartilage)
and adult chondrocytes, requiring greater than 40 cycles to
identify message in resting cells. The human chondrosarcoma
cell line (CH-1), which expresses mRNA for each of the B7
family members, was used as a positive control for costimu-
latory molecule expression (Fig. 5). Thus, these data revealed
that neocartilage-derived juvenile chondrocytes express
message for multiple inhibitory B7 family members.
Expression of chondromodulin-I, a recently identified
inhibitor of T cell proliferation
Chondromodulin-I (ChM-I) is a 25-kDa cysteine-rich trans-
membrane protein originally purified from bovine epiphyseal
cartilage that promotes chondrocyte growth (Hiraki et al.,
1999; Inoue et al., 1997), while inhibiting endothelial cell
growth (Hiraki et al., 1997). Although originally described as
cartilage-specific, Northern blot analysis of murine tissue
revealed expression of ChM-I in thymus, suggesting that the
protein may impact T cell development or function. Indeed,
recombinant human ChM-I has been found to be immuno-
suppressive both in vitro and in an animal model of antigen-
induced arthritis (Setoguchi et al., 2004). RT-PCR analysis
demonstrated high-level expression of ChM-I mRNA by
neocartilage-derived juvenile chondrocytes and by chondro-
cytes from adult articular cartilage (Fig. 5). Thus, ChM-I
expression by chondrocytes may directly disrupt T cell
function.
Expression of indoleamine 2,3-dioxygenase, a mediator of
immune evasion
Indoleamine 2,3-dioxygenase (IDO) is a heme-dependent
oxygenase that is thought to play a role in the induction of
immune tolerance (Mellor and Munn, 2004). A growing body
of evidence suggests that IDO activity is modulated in vitro
and in vivo by a variety of cytokines (Babcock and Carlin,
2000; MacKenzie et al., 1999) and by receptor-mediated
signaling through B7 family members (Munn et al., 2004). In
light of these data, we investigated whether neocartilage-
derived juvenile chondrocytes express IDO and whether IDOexpression plays a role in chondrocyte-mediated inhibition
of T cell proliferative responses. We showed that IDO mRNA
and protein synthesis by cultured neocartilage-derived
juvenile chondrocytes is upregulated following exogenous
treatment with proinflammatory cytokines, including inter-
leukin-1 (IL-1), tumor necrosis factor (TNF) alpha, stem cell
differentiation factor (SDF)-1 alpha, and interferon (IFN)-
gamma (Figs. 6a and b). Increased quantities of these
cytokines are reported to be present in joint synovial fluid
following trauma or as a consequence of degenerative
autoimmune arthritis (Lettesjo et al., 1998; Schlaak et al.,
1996). Importantly, inhibition of IDO with the selective
inhibitor 1-methyl tryptophan partially inhibited neocarti-
lage-derived juvenile chondrocyte immunosuppressive
64 H.D. Adkisson et al.activity, suggesting that this enzyme may also participate in
chondrocyte-mediated suppression of T cell responses.Discussion
Articular cartilage is considered to be an immune privileged
tissue, much like the anterior chamber of the eye. Allogeneic
transplantation either of fresh articular cartilage or of
chondrocytes harvested therefrom is reported to be well
tolerated and is generally accepted to not elicit an immune
response resulting in graft rejection, even in the absence of
immune suppressive therapy (Chesterman and Smith, 1968;
Elves and Zervas, 1974; Lance and Fisher, 1970; Maury et al.,
2007; Williams et al., 2007; Hendrickson et al., 1994;
Rahfoth et al., 1998; Robinson et al., 1990; Wakitani et al.,
1989). Successful transplantation of bioengineered neocar-
tilage into allogeneic and xenogeneic animal models suggests
that this bioengineered tissue is also immune privileged
((Feder et al., 2004; Lu et al., 2005); and data shown here).
It has been suggested that failure of the host immune
system to reject transplanted articular cartilage is due, in
part, to the unique architecture of this tissue. Articular
cartilage is avascular, and as such, entry of host immune cells
is restricted. Further, cartilage-associated chondrocytes are
buried in an extensive muccopolysaccharide-containing
extracellular matrix, a barrier which limits potential inter-
action between cells of the immune system and chondroctyes
(Elves and Zervas, 1974; Bacsich and Wyburn, 1947; Heyner,
1969). Although these physical barriers may play a role in
maintaining cartilage immune privilege, the data described
here support the concept that chondrocytes play a direct role
in preventing immune responses that may lead to the
destruction of transplanted neocartilage allografts. When
allogeneic T cells were cocultured with neocartilage-derived
juvenile chondrocytes, the chondrocytes failed to stimulate
alloantigen-specific T cell proliferation (Fig. 2). To evoke a
proliferative response from CD4+ T cells, allogeneic stimula-
tor cells must express unrelated MHC Class II molecules as
well as the costimulatory molecules B7-1 (CD80) and/or B7-2
(CD86) (reviewed in (Greenwald et al., 2005)). Under normal
conditions, juvenile chondrocytes, like most nonhemato-
poietic cells, do not express these proteins (Fig. 2c). Exposure
to IFN-gamma, which can occur as a consequence of cellular
activation in the transplant setting, induces surface expres-
sion of MHC Class I and II in chondrocytes, but not B7-1 (CD80)
and B7-2 (CD86) (Fig. 2c). Thus, the nonimmunogenic
properties of neocartilage-derived juvenile chondrocytes
may be attributed to their failure to provide adequate T
cell costimulation. Surprisingly, adult chondrocytes, which
constitutively express B7-1 (CD80) and B7-2 (CD86) mRNAs,
and show up-regulated expression of MHC Class I and II
antigen on IFN-gamma treatment (Fig. 3b), also were unable
to elicit T cell proliferation in the MLCR (not shown). This
intriguing observation suggested that both juvenile and adult
chondrocytes actively suppress immune responses.
The immune suppressive action of neocartilage-derived
juvenile chondrocytes was confirmed using alloantigen-acti-
vated PBL (Fig 4a). The inhibition of polyclonally activated
CD4+ T cells by both juvenile and adult chondrocytes revealed
that chondrocyte-mediated suppression of CD4+ T cell
proliferation does not require accessory cells (Fig. 4b).Further, transwell studies revealed that direct T cell contact
with chondrocytes was required to attenuate T cell prolifer-
ation (Fig. 4c). That chondrocytes are capable of inhibiting T
cell receptor-mediated T cell proliferation via direct cell–cell
contact was an unexpected finding and suggested that these
cells actively function to maintain balance between tolerance
and autoimmunity within the joint. It is noteworthy that a
human stem cell population, mesenchymal stem cells, is
reported to actively suppress immune responses. Although no
consensus mechanism has been described for immune sup-
pression by these cells, several reports indicate that suppres-
sion is cell–cell contact independent (Tse et al., 2003;
Klyushnenkova et al., 2005; Zhao et al., 2008). Thus, the
immune inhibitory properties of chondrocytes and mesenchy-
mal stem cells may function via distinct mechanisms.
We propose that chondrocytes may inhibit T cell prolifer-
ation via three distinct mechanisms. First, T cell proliferation
may be inhibited through inhibitory cell surface B7 costimu-
latory molecules. It was observed that mRNA for immune
inhibitory costimulatory molecules B7-H1, B7-DC, B7-H2, B7-
H3, and B7-H4 are present in unstimulated and/or IFN-
gamma-activated chondrocytes (Fig. 5). B7-DC is one of two
ligands that bind to the PD-1 receptor on T cells (reviewed in
(Greenwald et al., 2005)). Constitutive expression of B7-DC
by chondrocytes and the chondrosarcoma (CH-1) is intriguing,
as B7-DC expression is predominantly restricted to macro-
phages and dendritic cells (Liang et al., 2003). Signaling
through PD-1 inhibits T cell immune responses: B7-DC and the
other PD-1 ligand, B7-H1, inhibit T cell proliferation in vitro
(Freeman et al., 2000; Latchman et al., 2004; Carter et al.,
2002; Dong et al., 2002) and disruption of the PD-1 pathway in
vivo has been linked to both autoimmune disease (Nishimura
et al., 1999) and increased severity of graft versus host
disease (Blazar et al., 2003). B7-H3 was initially thought to be
stimulatory because it promoted T cell proliferation in vitro
(Chapoval et al., 2001); however, studies of B7-H3 knockout
mice indicate that B7-H3 may inhibit the Th1 subclass of T
cells, which have been implicated in transplant rejection
(Suh et al., 2003). B7-H4 blocks proliferation and cytokine
production by T cells in vitro and protects against autoim-
mune disease in vivo (Sica et al., 2003). Chondrocytes also
express high levels of B7-H2, and although this molecule has
not been associated with immune inhibition, it may aid in the
acceptance of transplanted allografts or xenografts by
promoting the development of Th2 rather than Th1 immune
responses (Harada et al., 2003). Thus, chondrocytes express
members of the B7 family that are immune suppressive and
may promote allograft or xenograft survival.
Second, we demonstrated that neocartilage-derived
juvenile and adult articular chondrocytes show high level
expression of ChM-I mRNA. ChM-I has pronounced immuno-
suppressive activity in an animal model of disease (Setoguchi
et al., 2004). This cysteine-rich transmembrane protein,
previously identified in cartilage and thymus (Hiraki et al.,
1997), has been shown to block in vitro proliferation of
polyclonally activated T cells (Setoguchi et al., 2004).
Finally, we showed that the ability of neocartilage-
derived juvenile chondrocytes to suppress immune responses
in vitro is sensitive to an inhibitor of IDO (Fig. 6). It is
generally accepted that IDO prevents rejection of the fetus
during pregnancy (Munn et al., 1998), and that human
dendritic cells transduced with the IDO gene are capable of
65Immune evasion by neocartilage chondroctyespreventing in vitro T cell proliferation via a kynurenine
metabolite that is cytotoxic to B and NK cells (Terness et al.,
2002). This mechanism may also contribute to neocartilage
implant survival.
Our finding that chondrocytes derived from bioengi-
neered juvenile neocartilage lack the ability to evoke an
allogeneic response in vitro is in complete agreement with
that of Jobanputra et al. (Jobanputra et al., 1992) who
demonstrated that freshly dissociated chondrocytes derived
from human adult articular cartilage were unable to
stimulate the proliferation of allogeneic PBL in the MLCR.
More important, we show that cultured juvenile and adult
chondrocytes derived from human articular cartilage
display unique immunosuppressive properties requiring
cell–cell contact, and we identify three possible mechan-
isms underlying the suppressive action of neocartilage
chondrocytes. While instances of chondrocyte immunoge-
nicity have been reported for rodent species (Gertzbein and
Lance, 1976; Hyc et al., 1997; Moskalewski and Kawiak,
1966), the apparent disparity with the current human data
may be due to the presence of contaminating nonchondro-
genic cells, including endothelial cells from the epiphysis or
adipocytes from the fat pad, in the rodent cell preparations
used for study. Clean dissection of articular cartilage from
its underlying bony tissue components is technically
difficult due to the extremely thin nature of this tissue in
mice and rats.
In conclusion, allogeneic and xenogeneic transplantation of
bioengineered neocartilage derived from juvenile chondro-
cytes appears to be successful because the tissue is protected
from the host immune system by both passive and active
mechanisms. Cartilage-associated chondrocytes are separated
physically from immune cells (Elves and Zervas, 1974; Bacsich
and Wyburn, 1947; Heyner, 1969), and chondrocytes derived
from juvenile neocartilage do not express cell surface
molecules that promote T cell responses. Further, chondro-
cytes are immunosuppressive, and inhibitory B7 molecules,
ChM-I and/or IDO, may mediate immune suppression. Due to
their unique immunological properties and an inherent
enhanced ability to synthesize cartilage matrix, juvenile
articular chondrocytes derived from allogeneic donor tissue
may have therapeutic applications in cartilage repair.Methods
Human subjects
Articular cartilage and bone marrow were obtained from
deceased human donors within 96 h of death. Tissue was
procured by Mid-America Transplant Services (St. Louis, MO),
Cell Dynamics, LLC (Smyrna, GA), and National Disease
Research Interchange (Philadelphia, PA), and informed con-
sent for use in medical research was obtained. Of 28 samples
analyzed, 19 were obtained from juvenile donor tissue (birth
to 14 years of age; mean 2.3 years) and 9 were from adult
donor tissue (21 to 54 years of age; mean 35.9 years). Donors
were screened for communicable disease agents, and only
donors with negative serology reports were used. Communi-
cable disease test results were typically reported within 48–
72 h, and tissues were stored in physiologically buffered
solution at 4 °C until test results were received.Neocartilage production and dissociation
Juvenile articular chondrocyteswere isolatedandneocartilage
disks grown to Days 45–60 of culture as described by Adkisson
et al. (Adkisson et al., 2001). Briefly, cadaveric donor articular
cartilage was cleaned of adventitious tissue by sharp dissec-
tion, and chondrocytes were enzymatically released by brief
treatment with pronase, followed by overnight digestion with
collagenase and hyaluronidase. Cells were washed, counted,
and subsequently seeded into tissue culture plastic at a density
of 1×106 cells per/mL in HL-1, a chemically defined medium
manufactured by Cambrex Biosciences, containing ascorbate
and glutamine. In the absence of three-dimensional scaffolds,
juvenile (in contrast to adult chondrocytes) were previously
demonstrated to aggregate and produce an hyaline extracel-
lular matrix (ECM) resembling that of juvenile articular
cartilage (Feder et al., 2004; Lu et al., 2005). These cultures
retain their native phenotype by assembling an ECM showing
positive staining for collagen types II, IX, and XI, with no
measurable type I collagen (Feder et al., 2004; Lu et al., 2005).
For immunophenotyping experiments, two neocartilage
disks prepared from each individual donor were digested for
12 h in HL-1 medium (Cambrex BioScience, Rockland, ME)
containing 60 Units/mL CLS4 collagenase (Worthington, Lake-
wood, NJ) and 50 Units/mL hyaluronidase (type VIII, Sigma, St.
Louis, MO). Dissociated chondrocytes were washed twice in
RPMI 1640 medium containing 2% FBS and resuspended in HL-1
medium. Cells were counted and diluted to 1×106/mL in RPMI
1640 media containing 10% heat-inactivated human AB serum
and 10 mM HEPES. Cells were stored on ice prior to use.
Adult chondrocytes harvested from cadaveric joints were
maintained in monolayer culture using the same conditions
described above for juvenile chondrocytes. Under such
conditions, adult chondrocytes fail to produce an ECM-rich
neocartilage because of their reduced synthetic capacity
relative to juvenile chondrocytes (Adkisson et al., 2001).
Therefore, complete dissociation of chondrocyte monolayers
prepared with adult chondrocytes required only 4–6 h, using
the conditions described above.
Generation of bone marrow dendritic cells
Bonemarrowmononuclear cells served as a source of progenitor
cells that were expanded and differentiated into dendritic cells
in vitro. Bone marrow dendritic cells (BMDC) served as positive
controls for flow cytometric analyses and MLCR assays. The
medullary space of the femur, tibia, and fibula from each
donated knee was flushed with Ca2+/Mg2+-free PBS to collect
bone marrow cells. Mononuclear cells were recovered from
these cell suspensions using Histopaque 1077 (Sigma), and cells
were washed three times in Ca2+/Mg2+-free PBS and cryopre-
served. BMDC were generated using a method adapted from
Caux andDubois (Caux andDubois, 2001). Briefly, cryopreserved
bone marrow mononuclear cells were rapidly thawed at 37 °C
and incubated at a concentration of 3×106 cells/5 mL of X-Vivo
15 serum-free medium (Cambrex, Walkersville, MD) containing
Flt-3 ligand (100 ng/mL), TNF-alpha (10 ng/mL), GM-SCF
(100 ng/mL), IL-3 (10 ng/mL), IL-7 (10 ng/mL), SCF (10 ng/
mL), 20mMHEPES, 2mM L-glutamine, and 5% human AB serum.
All cytokines were purchased from Peprotech Inc. (Rocky Hill,
NJ). On Day 7 of culture, these cultures were split 1:4 and
maintained as described for an additional 72 h. On Day 10 of
66 H.D. Adkisson et al.culture, IL-4 (20 ng/mL) was added to promote maturation of
immature dendritic cells during the final 72 h of culture.
Mixed lymphocyte–chondrocyte reaction assays
Immunogenicity of chondrocytes was assessed using mixed
lymphocyte–chondrocyte reaction (MLCR) assays. For these
assays, chondrocytes (102 to 104/well) were evaluated for their
ability to stimulate proliferation of human peripheral blood
lymphocytes (PBL; 2×105/well) from unrelated normal donors.
BMDC prepared from the same donor tissue used to generate
neocartilage grafts in vitro served as a positive control. Cells
were cultured in RPMI 1640medium containing 10% FBS, 15mM
HEPES, 2 mM L-glutamine, 1 mM MEM sodium pyruvate, MEM
nonessential amino acids, penicillin-streptomycin, and 5×
10−5 M ß–mercaptoethanol. Stimulator cells were gamma-
irradiated (3000 rad) toprevent proliferation. In vitroprolifera-
tion of allogeneic PBLwas quantitated on Days 5–6 of coculture
after an 18-h pulse with tritiated thymidine (Amersham, 1 μCi/
mL, Piscataway, NJ). Cells were lysed in water and released
DNA was bound to glass fiber filters using an automated cell
harvester (Tomtec, Hamden, CT). The filters were dried and
counted in a Wallac MicroBeta Scintillation Counter (Perkin
Elmer, Boston, MA). Results are expressed as mean counts per
minute (CPM) for replicates of three to six±SEM.
Immune suppression assays
The immune suppressive activity of chondrocytes was assessed
usingpolyclonally activatedCD4+ T lymphocytes. Briefly, human
peripheral blood mononuclear cells (PBMC) were recovered
using Histopaque 1077, and CD4+ T lymphocytes were purified
from this mononuclear cell fraction using magnetic-activated
cell separation (MACS) columns (Miltenyi Biotec, Auburn, CA).
To assess the immunosuppressive activity of chondrocytes,
naïve T cells (1×105/well) were activated in 96-well plates by
crosslinking the T cell receptor complex (TCR/CD3) with
0.01 μg/mL of plate-bound anti-CD3 and the costimulator re-
ceptor (CD28) with 5 μg/mL anti-CD28 added to culture media.
Irradiated chondrocytes were added to activated lymphocytes.
In some experiments, activated lymphocytes were separated
from chondrocytes using Anapore Transwells (Nunc, 0.2-μm
pore size). Cells were cultured for 72 h, and tritiated thymidine
was added to each well for the final 18 h of incubation.
Flow cytometric analyses
Chondrocytes and BMDC were evaluated for expression of cell
surface markers commonly associated with antigen presenting
cells using three-color flow cytometry. Cells were evaluated
using antibodies directed against HLA-DR, CD11c, CD123, HLA-
ABC, CD40, B7-1, and B7-2, and the leukocyte lineage (LIN)
markers CD3, CD14, CD16, CD19, CD20, or CD56; and negative
control antibodies. Data were analyzed using CellQuest
software.
RT-PCR characterization of costimulatory molecule
expression
The expression of mRNA specific to the B7 family of costimu-
latory molecules, including B7-1 (CD80), B7-2 (CD86), B7-H1
(PD-L1), B7-DC (PD-L2), B7-H2 (ICOS), B7-H3, and B7-H4 wasassessed using reverse-transcription polymerase chain reaction
(RT-PCR). Total RNA was extracted from disrupted neocartilage
disks using Qbiogene Fast RNA Pro Green Kit (Qbiogene Inc.,
Carlsbad, CA) followed by RNeasy Mini Kit (Qiagen Inc., Valen-
cia, CA) column purification with DNase digestion (Qiagen). A
single tube RT-PCR with 0.5 μg of RNA was performed in a 25-μL
reactionmixture using RNA-specific primers and the EZ rTth RNA
PCR kit (Perkin Elmer/Applied Biosystems). All experiments
were performed three times on individual donors. Primers
were selected using DNA Star software to ensure specificity,
and primers were purchased from Sigma Genosys: B7-1 (sense,
5′-GCCATCAACACAACAGTTTCCCAA-3′; antisense, 5′-CAGGG-
CGTACACTTTCCCTTCTCAA-3′, length 313 bp), B7-2 (sense, 5′-
CTCTCTGGTGCTGCTCCTCTGAA-3′; antisense, 5′-CTGTGGGCT-
TTTTGTGATGGATGATAC-3′, length 298 bp), B7-H1 (sense, 5′-
CTACCCCAAGGCCGAAGTCA-3′; antisense, 5′-CCCAGAATTAC-
CAAGTGAGTCC-3′, length 258 bp), B7-DC (sense, 5′-ACCCTGG-
AATGCAACTTTGACACT-3′; antisense, 5′-ACTTGGACTTGAGGTA-
TGTGGAACGA-3′, length 167 bp), B7-H2 (sense, 5′-GACTTCTCC-
CTGCGCTTGTTCA-3′; antisense, 5′-GCAGGCTGTTGTCCGTCT-
TATTG-3′, length 256 bp), B7-H3 (sense, 5′-CGTGGGGCTGTCT-
GTCTGTCTCATT-3′; antisense, 5′-TCAGGCTATTTCTTGTCCAT-
CATCTTCT-3′, length 196 bp), and B7-H4 (sense, 5′-CACTCAT-
CATTGGCTTTGGTATTTCAG-3′; antisense, 5′-CGACAGCTCATCT-
TTGCCTTCTTTG-3′, length 203 bp). IFN-gamma-induced human
chondrosarcoma RNA (Ch-1 cells were a gift from Linda Sandell,
Washington University, St. Louis, MO) was used as a positive
control for B7 family member gene expression.
RT-PCR characterization of chondromodulin-I and
indoleamine 2,3-dioxygenase
RT-PCR analysis of ChM-I and IDO gene expression was carried
out using the following probes: ChM-I (sense, 5′-
AGAAAATTCTCTTATCTGGGTGGCTGTA-3′; antisense, 5′-
CTCTGGATTTCTTTTGGATAGGTTGGT-3′, length 135 bp),
IDO (sense, 5′-AGGCAACCCCCAGCTATCAGAC-3′; antisense,
5′-TCAGGGAGACCAGAGCTTTCACAC-3′, length 314 bp). The
housekeeping gene, glyceraldehyde-3-phosphate dehydro-
genase (GAP) was used as the loading control for RNA; GAP
(sense, 5′-GCAAATTCCATGGCACCGTCA-3′; antisense, 5′-
CAGGGGTGCTAAGCAGTTGG-3′, length 320 bp).
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